logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics forming new partnership for chronic pain study in retired athletes

The chronic pain clinical trial is aimed at the large market for chronic pain treatment in retired athletes where medical cannabis may provide a safe and effective treatment.

Zelira Therapeutics Ltd - Zelira Therapeutics forms new partnership with Levin Growing Pty Ltd to undertake chronic pain study
Levin will fund the trial with Zelira to design and manage the study

Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) has entered into a non-binding Heads of Agreement with Melbourne-based cannabis company Levin Growing Pty Ltd to develop a novel cannabinoid treatment for sports-related chronic pain.

Levin will fund the trial with Zelira to design and manage the study aimed at assisting retired professional and amateur athletes using its proprietary cannabinoid formulation.

Studies demonstrate that retired athletes are more likely to suffer chronic pain and associated conditions such as depression and anxiety because of injuries over long periods of time.

Medical cannabis may provide a safe and effective targeted treatment option for this large cohort although the clinical data is currently limited.

Clinical trial to assess safety

Zelira’s partnership with Levin will seek to address this unmet need by undertaking a clinical trial, at Levin’s expense, to assess the safety and efficacy of a proprietary cannabinoid formulation tailored for sports-related chronic pain.

The proposed partnership will leverage Zelira’s leading intellectual property portfolio and expertise in clinical trial design for medical cannabis, including chronic pain, along with Levin’s advisory team and network of retired professional athletes.

Levin chairman Matt Syme said: “Zelira’s clinical expertise and our joint focus on the medical science behind cannabis as a pain treatment provides hope for long overdue, non-addictive relief options to chronic, sports-related pain sufferers.”

Profits shared

Upon the Heads of Agreement becoming binding, Zelira will license a specific formulation to Levin to support the chronic pain clinical trial in retired athletes.

Zelira will hold marketing rights for North and South America with Levin retaining rights to all other world markets and profits will be shared equally between both companies.

Negotiations will begin immediately to prepare a definitive and binding agreement, which will be conditional upon acceptance of the clinical trial design by both parties.

This work expands and complements Zelira’s strategic interests in chronic pain while maintaining focus on the global launch of its proprietary insomnia and HOPETM products.

Opioid Reduction Study in Melbourne

Zelira has made other advances in using its proprietary products, most notably opioid reduction for people suffering chronic pain.

It is currently involved in an Opioid Reduction Study in collaboration with St Vincent’s Hospital in Melbourne.

It is undertaking a study to assess the safety and effectiveness of medical cannabis to reduce opioid dependence.

Prescription opioids treating chronic pain are linked to serious side effects, which is a growing global crisis.

Quick facts: Zelira Therapeutics Ltd

Price: 0.053 AUD

ASX:ZLD
Market: ASX
Market Cap: $60.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read